Liu Qifa
- 3 Bien • 1 avis
- 33 années d'expérience
- Chine, Pékin, Lu Daopei
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.
Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.
She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.
Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.
Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.
He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.
He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.
Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.
He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.
Le Prof. Omay est l'auteur de plus de 65 articles scientifiques en hématologie et est spécialisé dans les greffes de cellules souches, formé dans des institutions prestigieuses, notamment l'Université Hacettepe et l'Université Ege.
Le Prof. Baytan est spécialisé dans les cancers de l'enfant et les traitements contre la leucémie, avec plus de 15 articles publiés dans des revues internationales.
Le Dr Omer Dogru est spécialisé en hématologie et oncologie pédiatriques, avec une vaste expérience en transplantation de cellules souches haplo-identiques à l'hôpital universitaire Biruni.
Professeur agrégé en hématologie avec plus de 50 publications – Le Dr Eren est spécialisé en transplantation de cellules souches haplo-identiques à l'Hôpital Universitaire Biruni.
Avec plus de 40 ans d'expérience en hématologie-oncologie pédiatrique, le Dr Apak est spécialisé dans les traitements avancés tels que la transplantation de moelle osseuse et la thérapie par cellules CAR T.
Le Dr Prakash Pandit est spécialisé dans les techniques avancées de radio-oncologie au HCG Manavata Cancer Centre.
Est spécialisé(e) dans la transplantation de cellules souches haplo-identiques à l'Hôpital Liv Vadistanbul – un centre de premier plan pour les procédures hématologiques complexes.
Le professeur associé Ali Hakan Kaya est spécialisé dans la greffe de cellules souches haplo-identiques à l'hôpital universitaire Biruni, avec plus d'une décennie d'expérience en hématologie.
Plus de 30 ans d'expérience spécialisée en hématologie-oncologie pédiatrique – le Dr Lopez Ibor dirige l'Unité d'Hématologie et d'Oncologie Pédiatrique du Groupe HM.
Le Dr Girish Badarkhe est spécialisé dans les greffes de moelle osseuse, avec plus de 13 ans d'expérience dans les cas d'hématologie complexes au HCG Manavata Cancer Centre.